Purpose

The goal of this clinical study is to compare Felix NeuroAI Wristband and sham device in patients with essential tremor. The main question it aims to answer is: • Is Felix a safe and efficacious treatment for patients with essential tremor? Participants will be treated with either Felix or Sham for a period of up to 90 days. After that, they will be eligible to participate in a long-term, open-label study and be treated with Felix.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • At least 18 years of age. - Willing to provide written, informed consent to participate in the study. - A clinical diagnosis of ET by a movement disorder specialist. - For the dominant hand, a tremor severity score of 2 or higher as measured by one of the TETRAS Performance Subscale (PS) tasks (items 4, 6, 7, and 8) and a total score of 7 or higher across these items. If applicable, this must be met while the patient is on ET treatment. - Stable dosage of anti-tremor medications, if applicable, for 30 days prior to study entry. - Stable dosage of antidepressant medications, if applicable, for 90 days prior to study entry. - Familiar with operating a touch-screen smartphone and connecting to Wi-Fi internet at home. - If necessary, have a dedicated caregiver to help with study required activities, such as putting on the study device, etc. - Willing to comply with study protocol requirements including: 1. Remaining on a stable dosage of anti-tremor and antidepressant medications, if applicable, during the course of the study. 2. Do not start any new anti-tremor treatment during the course of the study (except the assigned treatment in the study). 3. Remaining on stable caffeine consumption, if applicable, during the course of the study. 4. No alcohol or marijuana consumption the day before a study visit. 5. Do not share study/device-related information on the internet or with other study patients.

Exclusion Criteria

  • Prior limb amputation or any known symptomatic peripheral neuropathy condition of the involved upper extremity. - Prior surgical intervention for ET such as deep brain stimulation or thalamotomy. - Moderate to severe alcohol use disorder (AUD) as per Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) (the presence of at least 4 symptoms or more). - Any current drug abuse. - Use of recreational drugs other than marijuana. - Current unstable epileptic conditions with a seizure within 6 months of study entry. - Other possible causes of tremor such as drug-induced tremor, enhanced physiological tremor, dystonia, and Parkinson's disease. - Pregnant or nursing subjects and those who plan pregnancy during the course of the study. - Swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at the stimulation site. - Known allergy to adhesive bandages. - The presence of any cognitive or other impairment that in the judgement of the investigator will impede the assessment of study outcomes. - Botulinum Toxin injection for hand tremor within 4 months prior to study enrollment. - History of use of other transcutaneous afferent patterned stimulation (TAPS) devices such as Cala Trio. - Subject is currently participating or has participated in another interventional clinical trial in the last 30 days which may confound the results of this study, unless approved by the Sponsor. - Subject is unable to communicate with the investigator and study staff. - Any health condition that in the investigator's opinion should preclude participation in this study.

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
Subjects will be randomized in a 2:1 ratio to Felix and Sham and be followed for 90 days. After the 90-day follow-up, all subjects will be encouraged to participate in the continued access phase, where subjects randomized to the Sham arm will cross over to Felix and all subjects will be followed up to 1 year (from randomization).
Primary Purpose
Treatment
Masking
Double (Participant, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Felix NeuroAI Wristband
  • Device: Felix NeuroAI Wristband
    The Felix NeuroAI Wristband (Felix) is a wrist-worn, noninvasive, transcutaneous neurostimulation system. Using a proprietary artificial intelligence (AI) algorithm, stimulation will be automatically adapted to patient's needs with the goal to provide full day relief of upper limb tremor.
Sham Comparator
Sham Device
  • Device: Sham Device
    The sham device has the same exterior appearance and components as the Felix device and is used the same way (without delivering the treatment).

Recruiting Locations

The University Of Kansas Medical Center
Kansas City, Kansas 66160
Contact:
Rajesh Pahwa, MD

More Details

Status
Recruiting
Sponsor
Fasikl Inc.

Study Contact

Head of Clinical Affairs
1-507-403-7680
felixsupport@fasikl.com

Detailed Description

The TRANQUIL study is a prospective, randomized, sham-controlled, double-blinded, multi-center, multi-region trial. The objective of this clinical investigation is to evaluate the safety and effectiveness of the Felix NeuroAI Wristband to aid in the relief of upper limb tremor in adults with essential tremor (ET).

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.